Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer

Background: Oxaliplatin and capecitabine (CapeOX) combined with cetuximab is rarely used to treat advanced and metastatic colorectal cancer (mCRC). The present study aimed to clarify the clinical benefits of this treatment regimen when used as a first-line therapy in patients with expanded RAS/BRAF/...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwamoto, Shigeyoshi, Maeda, Hiromichi, Hazama, Shoichi, Oba, Koji, Okayama, Naoko, Suehiro, Yutaka, Yamasaki, Takahiro, Suzuki, Nobuaki, Nagano, Hiroaki, Sakamoto, Junichi, Mishima, Hideyuki, Nagata, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277612/
https://www.ncbi.nlm.nih.gov/pubmed/30519308
http://dx.doi.org/10.7150/jca.26840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277612/
https://www.ncbi.nlm.nih.gov/pubmed/30519308
http://dx.doi.org/10.7150/jca.26840

Ejemplares similares